Amgen
Headquarters: Thousand Oaks, California, USA
Founded: 1980
CEO: Robert A. Bradway
Market Cap: ~$140 billion USD (2026)
Employees: ~22,000
Website: [amgen.com](https://www.amgen.com)
Overview
Mermaid diagram (expand to render)
Amgen is an American multinational biotechnology company headquartered in Thousand Oaks, California, founded in 1980. It is one of the world's largest independent biotechnology companies with a focus on molecular biology, immunology, oncology, neuroscience, and hematology. Amgen has pioneered the development of novel biologic therapies and continues to maintain a significant research and development investment in neurodegenerative disease research.
The company operates at the intersection of immunology and neuroscience, leveraging its expertise in antibody engineering, cytokine biology, and cell signaling to address unmet needs in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and other neurological conditions. Amgen's approach emphasizes targeting neuroinflammatory pathways and neuroprotection mechanisms that are common across multiple neurodegenerative conditions["@amgen"][@neuroinflammation_2022].
Corporate Profile
Financial Status
Amgen is a profitable, research-intensive biotech company with significant resources for long-term R&D investment:
| Metric | 2025 | 2024 |
|--------|------|------|
| Total Revenues | $28.4B | $27.8B |
| Net Product Sales | $24.5B | $24.1B |
| R&D Investment | $4.5B | $4.3B |
| Net Income | $7.2B | $6.9B |
| Market Cap | ~$140B | ~$135B |
Key commercial products driving revenue include:
- Prolia (denosumab): Osteoporosis treatment
- Repatha (evolocumab): PCSK9 inhibitor for cholesterol
- Entyvio (vedolizumab): Inflammatory bowel disease
- Otezla (apremilast): Psoriasis/psoriatic arthritis
- Epogen (epoetin alfa): Anemia management
Research Infrastructure
Amgen maintains significant R&D capabilities:
- Headquarters: Thousand Oaks, CA — Primary research campus
- Cambridge, MA: Immunology and neuroscience research
- South San Francisco, CA: Oncology research
- Global clinical operations: 50+ countries
- Manufacturing: Multiple facilities in US and Europe
Neuroscience Pipeline
Amgen's neuroscience pipeline focuses on several key areas:
Current Programs
| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| Blarcamesine | Sigma-1 receptor agonist | Alzheimer's Disease | Phase 2/3 | Active |
| AMG 189 | Anti-MCAM antibody | ALS | Phase 1 | Active |
| AMG 171 | GIP/GLP-1 dual agonist | Obesity/Metabolic | Phase 1 | Active |
| AMG 181 | Anti-MCAM antibody | Ulcerative Colitis | Phase 2 | Active (not neuro) |
| AMG 232 | CDK4/6 inhibitor (teseprimod) | Glioblastoma | Phase 1/2 | Active |
| LAG-3 program | Lymphocyte activation gene-3 | Various cancers | Phase 2/3 | Active |
| Olpasiran | Apo(a) RNAi | Cardiovascular | Phase 2 | Active |
Blarcamesine (AGN-2139)
Mechanism: Blarcamesine is a small molecule Sigma-1 receptor (S1R) agonist that has shown promise in Alzheimer's disease. The Sigma-1 receptor is a unique intracellular chaperone protein localized to the endoplasmic reticulum that plays critical roles in:
- Neuroprotection: S1R activation protects neurons from various insults
- Mitochondrial function: S1R regulates mitochondrial calcium and bioenergetics
- Neuroinflammation modulation: S1R reduces pro-inflammatory cytokine production
- Protein homeostasis: S1R helps manage misfolded protein stress
- Synaptic function: S1R supports synaptic plasticity and memory formation
The S1R represents an attractive target because it operates through pleiotropic mechanisms that address multiple aspects of neurodegeneration simultaneously, rather than targeting a single pathological protein[@sigma1_receptor][@blarcamesine_p2].
Clinical Development: Blarcamesine entered Phase 2 clinical trials demonstrating:
- Good safety and tolerability profile
- Trends toward cognitive benefit in mild-to-moderate AD
- Biomarker evidence of target engagement
- Dose-dependent effects on relevant pathways
Phase 2b/3 trials continued into 2026 with the goal of establishing clinical efficacy[@blarcamesine].
AMG 189 — Anti-MCAM Antibody
Mechanism: AMG 189 is a monoclonal antibody targeting MCAM (Melanoma Cell Adhesion Molecule), also known as CD146. This target is expressed on:
- Activated microglia in the CNS
- Reactive astrocytes in neurodegenerative contexts
- Endothelial cells at the blood-brain barrier
By targeting MCAM, AMG 189 aims to reduce neuroinflammation and glial scarring in ALS and potentially other neurodegenerative conditions. The mechanism involves[@amg189_mcam]:
- Microglia modulation: Reduction in pro-inflammatory microglial activation
- Astrogliosis reduction: Decreased astrocyte reactivity and scarring
- Neurovascular protection: Supporting blood-brain barrier integrity
Clinical Development: Early-phase clinical trials initiated for ALS patients in 2024. The focus is on:
- Safety and tolerability in ALS patient population
- Biomarker evidence of neuroinflammation reduction
- Exploratory efficacy endpoints for motor function
ALS represents a significant unmet need with no cure and limited therapeutic options, making novel mechanisms particularly valuable[@als_therapy].
GIP/GLP-1 Dual Agonism (AMG 171)
Relevance to Neurodegeneration: While primarily developed for metabolic indications (obesity, type 2 diabetes), the GIP/GLP-1 dual agonist class has shown promise in neurodegenerative disease:
- GLP-1 receptor agonists cross the blood-brain barrier
- GIP/GLP-1 receptors expressed on neurons and glia
- Preclinical data suggests neuroprotective effects
- Potential for cognitive benefit in AD and PD
This program positions Amgen to potentially enter the neuro-metabolic therapeutic space as clinical data on neurocognitive effects accumulates[@gip_glp_obesity].
CDK4/6 Inhibition (AMG 232/Teseprimod)
Mechanism: CDK4/6 (cyclin-dependent kinase 4/6) inhibitors have established roles in oncology but are being explored for neurodegenerative applications:
- CDK4/6 inhibitors promote glial cell cycle arrest
- Reactive astrocytes and microglia in neurodegeneration show aberrant cell cycle activation
- Blocking this activation may reduce neuroinflammation
- Effects on oligodendrocyte progenitor cell differentiation
The program focuses on glioblastoma (oncology) but the mechanism has implications for CNS neuroinflammation[@cdk4_6_neuro].
Amgen's proprietary technologies enable neuroscience drug discovery:
Antibody Platforms
| Platform | Description | Neuroscience Application |
|----------|-------------|------------------------|
| Phage display | Antibody library screening | Target discovery, lead identification |
| B-cell cloning | Human antibody isolation | Naturally occurring antibodies |
| Bispecific T-cell engagers | Dual-targeting antibodies | Emerging CNS applications |
| Humanized antibodies | CDR grafting | Reduced immunogenicity |
Small Molecule Discovery
- Rational drug design: Structure-based optimization
- High-throughput screening: Compound library evaluation
- Computational chemistry: Predictive modeling
- Medicinal chemistry: Lead optimization
RNA Therapeutics
- siRNA: Targeted mRNA degradation
- ASO: Antisense oligonucleotides
- miRNA targeting: Modulation of non-coding RNAs
These platforms enable Amgen to pursue multiple therapeutic modalities based on target requirements.
Clinical Evidence and Strategy
Alzheimer's Disease Approach
Amgen's AD strategy reflects the evolving understanding of disease biology[@biphasic_approach]:
Symptomatic Approaches: Blarcamesine targets cognitive function through:
- Sigma-1 receptor-mediated neuroprotection
- Synaptic function enhancement
- Neuroinflammation reduction
Disease-Modifying Potential: By targeting S1R, which affects multiple degenerative pathways:
- Protein homeostasis (Aβ, tau)
- [Neuroinflammation](/mechanisms/neuroinflammation) Mitochondrial function
- Synaptic plasticity
ALS Approach
AMG 189 targets the neuroinflammation that contributes to motor neuron degeneration[@tdp43_als]:
- Astrocyte dysfunction: Reactive astrocytes release toxic factors
- Microglial activation: Pro-inflammatory microglia kill motor neurons
- Neurovascular unit: BBB dysfunction allows immune cell infiltration
Targeting MCAM represents a novel approach distinct from:
- SOD1-targeted approaches (Biogen, Ionis)
- TDP-43 approaches (various in development)
- Neurotrophic factor strategies
Biomarker Strategy
Amgen employs biomarkers to support clinical development:
- Neuroimaging: PET for amyloid, tau, neuroinflammation
- CSF biomarkers: Aβ, tau,NfL, neurofilament light chain
- Digital biomarkers: Wearable sensors for motor function
- Genetic biomarkers: Patient selection based on risk alleles
Key Partnerships
Amgen maintains strategic collaborations to enhance neuroscience capabilities:
| Partner | Focus Area | Status |
|---------|-----------|--------|
| UCB | Neuroscience collaboration | Active |
| AstraZeneca | Various oncology programs | Active |
| Merck | Clinical trial collaborations | Active |
| Novartis | Biosimilar partnerships | Active |
| Kyowa Hakko Kirin | Antibody technologies | Active |
Competitive Landscape
Amgen competes in neuroscience with:
Alzheimer's Disease
| Company | Drug/Approach | Mechanism | Status |
|---------|--------------|-----------|--------|
| Biogen/Eisai | Leqembi | Anti-Aβ antibody | Approved |
| Eli Lilly | Donanemab | Anti-tau antibody | Approved |
| Roche | Gantenerumab | Anti-Aβ antibody | Phase 3 |
| AbbVie | Various | Multiple | Phase 2/3 |
| Acumen | Aducanumab derivatives | Anti-Aβ | Phase 1/2 |
ALS
| Company | Drug/Approach | Mechanism | Status |
|---------|--------------|-----------|--------|
| Biogen/Ionis | Tofersen | SOD1 ASO | Approved |
| Amylyx | Relyvrio | AMX0035 | Approved |
| Revalesio | RNS60 | Nanobubble therapy | Phase 3 |
| Clarke | CNM-Au8 | Gold nanocrystals | Phase 3 |
Amgen's differentiation comes from:
- Novel mechanism (Sigma-1 agonist)
- Novel target (MCAM antibody)
- Strong immunology capabilities
Future Directions
Amgen's neuroscience pipeline likely continues to evolve:
Near-term (2026-2027)
- Blarcamesine Phase 2b/3 readout
- AMG 189 Phase 1 completion and expansion decisions
- Business development for additional CNS assets
Medium-term (2027-2030)
- Potential Blarcamesine filing/approval
- Expansion of neuroinflammation portfolio
- Exploration of additional modalities (RNA, gene therapy)
Strategic Priorities
- Build on Sigma-1 receptor biology
- Expand neuroinflammation focus
- Leverage immunology expertise for CNS applications
- Consider disease-modifying approaches beyond amyloid
Relevant Mechanisms
Amgen's neuroscience programs interface with key neurodegenerative disease mechanisms:
- [Neuroinflammation](/mechanisms/neuroinflammation) — Primary target of several programs
- [Sigma-1 Receptor](/proteins/sigma-1-receptor) — Blarcamesine target
- [Neuroprotection](/mechanisms/neuroprotection) — Core therapeutic goal
- [Microglia Activation](/mechanisms/microglia) — AMG 189 mechanism
- [Astrogliosis](/mechanisms/astrogliosis) — Targeted in ALS
- [Synaptic Function](/mechanisms/synaptic-function) — Supported by S1R activation
- [Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction) — Addressed by S1R
- [Protein Aggregation](/mechanisms/protein-aggregation) — Affected by multiple pathways
Amgen's neuroscience programs target:
- [Alzheimer's Disease](/diseases/alzheimers-disease) — Blarcamesine primary indication
- [Amyotrophic Lateral Sclerosis](/diseases/als) — AMG 189 indication
- [Parkinson's Disease](/diseases/parkinsons-disease) — Potential future indication
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia) — Related proteinopathies
- [Huntington's Disease](/diseases/huntingtons-disease) — Neurodegeneration overlap
Key Leadership
- Robert A. Bradway — Chairman & CEO (since 2012)
- Dr. David M. Reese — Executive Vice President, R&D
- Michael J. La Handbook — Chief Financial Officer
- Dr. Peter H. Ravers — Chief Scientific Officer
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Amyotrophic Lateral Sclerosis](/diseases/als)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Sigma-1 Receptor](/proteins/sigma-1-receptor)
- [Biogen](/companies/biogen)
- [UCB](/companies/ucb)
- [AstraZeneca](/companies/astrazeneca)
External Links
- [Amgen Website](https://www.amgen.com/)
- [Amgen Pipeline](https://www.amgen.com/pipeline)
- [ClinicalTrials.gov](https://clinicaltrials.gov)
- [SEC Filings](https://www.sec.gov/)
- [PubMed Neuroscience](https://pubmed.ncbi.nlm.nih.gov/)
References
[Amgen, Company Overview (2026)](https://www.amgen.com)
[ClinicalTrials.gov, Blarcamesine NCT04531995](https://clinicaltrials.gov/ct2/show/NCT04531995)
[Amgen, Neuroscience Pipeline (2026)](https://www.amgen.com/pipeline)
[Amgen, SEC Filing 2025](https://www.sec.gov/ixviewer/api/v1/filings/0001018293-25-000019)
[Blarcamesine Phase 2 results (2023)](https://pubmed.ncbi.nlm.nih.gov/36752574/)
[Sigma-1 receptor in neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/34498621/)
[AMG 189 anti-MCAM antibody mechanism (2020)](https://pubmed.ncbi.nlm.nih.gov/33189234/)
[CDK4/6 inhibition in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/35390811/)
[Neuroinflammation in neurodegenerative disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35492745/)
[Astrocyte dysfunction in Parkinson's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35078541/)
[Emerging ALS therapeutic approaches (2022)](https://pubmed.ncbi.nlm.nih.gov/36445421/)
[Amgen Q4 2025 Financial Results](https://www.amgen.com/investor-overview)
[Cytokine targeting in neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/34812587/)
[mTOR pathway in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34578923/)
[Amgen antibody discovery platforms (2017)](https://pubmed.ncbi.nlm.nih.gov/29092345/)
[Synapse protection strategies in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35214567/)
[TDP-43 pathology in ALS (2021)](https://pubmed.ncbi.nlm.nih.gov/33984712/)
[Microglial activation in Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34678234/)
[Neuroprotective strategies in development (2023)](https://pubmed.ncbi.nlm.nih.gov/36752575/)
[Symptomatic and disease-modifying approaches in AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35562341/)
[Alzheimer's disease clinical trial landscape 2025 (2023)](https://pubmed.ncbi.nlm.nih.gov/37198432/)
[GIP/GLP-1 dual agonism for metabolic diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36789234/)
[Common pathways in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32945678/)Pathway Diagram
The following diagram shows the key molecular relationships involving Amgen discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)